Hematological Neoplasms

On April 1, 2024, the US Food and Drug Administration (FDA) granted approval to Kite, a Gilead Sciences subsidiary, for Yescarta (Axicabtagene Ciloleucel), a CAR-T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL) who are refractory to first-line chemotherapy immunotherapy or experience recurrence within 12 months of first-line chemotherapy immunotherapy.

Cancer treatment has come a long way, and one of the most promising advancements in recent years is the development of CAR-T cell therapy.

Yescarta, known by its generic name axicabtagene ciloleucel, is a groundbreaking CAR-T cell therapy.

On March 5, 2021, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta (axicabtagene ciloleucel), a groundbreaking treatment for adult patients with relapsed or refractory follicular lymphoma (FL) who have undergone at least two systemic therapies.

On March 5, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.

Yescarta (Axicabtagene Ciloleucel), a revolutionary CAR-T cell therapy, has garnered significant attention since its FDA approval in 2017. This article aims to provide a comprehensive overview of Yescarta, including its FDA approval history, indications, efficacy, safety profile, and potential future developments.

Yescarta, also known as Axicabtagene Ciloleucel (Axi-Cel) or 奕凯达 (阿基伦塞) in Chinese, is a chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen.

Yescarta (Axicabtagene ciloleucel, Axi-cel) has revolutionized the treatment landscape for lymphoma since its initial approval by the US FDA on October 18, 2017. As the world’s first chimeric antigen receptor T-cell (CAR-T) therapy for adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have received two or more lines of systemic therapy, Yescarta has ushered in a new era in lymphoma treatment.

In the realm of oncology, the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) has witnessed significant advancements over the past decade.